KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2025)

Ginkgo Bioworks Holdings filings provide 7 years of Common Equity readings, the most recent being $508.6 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 28.97% to $508.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $508.6 million, a 28.97% decrease, with the full-year FY2025 number at $508.6 million, down 28.97% from a year prior.
  • Common Equity hit $508.6 million in Q4 2025 for Ginkgo Bioworks Holdings, down from $559.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.7 billion in Q4 2022 to a low of $355.8 million in Q2 2021.
  • Median Common Equity over the past 5 years was $1.0 billion (2023), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Common Equity: soared 341.91% in 2022 and later plummeted 44.59% in 2024.
  • Ginkgo Bioworks Holdings' Common Equity stood at $1.6 billion in 2021, then increased by 10.78% to $1.7 billion in 2022, then crashed by 36.81% to $1.1 billion in 2023, then plummeted by 34.73% to $716.1 million in 2024, then fell by 28.97% to $508.6 million in 2025.
  • The last three reported values for Common Equity were $508.6 million (Q4 2025), $559.8 million (Q3 2025), and $613.0 million (Q2 2025) per Business Quant data.